Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for pa... ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. Mehr anzeigen
School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law...
Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an...
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO...
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19...
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.31 | -2.24800580131 | 13.79 | 15.19 | 12.85 | 1329680 | 14.44269654 | CS |
| 4 | 2.68 | 24.8148148148 | 10.8 | 15.19 | 10.6689 | 1366161 | 12.64008751 | CS |
| 12 | -2.53 | -15.8026233604 | 16.01 | 18.49 | 10.2 | 1336095 | 13.00012488 | CS |
| 26 | 2.34 | 21.0053859964 | 11.14 | 18.49 | 8.9055 | 1212635 | 13.32613177 | CS |
| 52 | 7.27 | 117.069243156 | 6.21 | 18.49 | 6.13 | 925190 | 11.84667036 | CS |
| 156 | 8.2 | 155.303030303 | 5.28 | 18.49 | 2.55 | 754966 | 9.00388585 | CS |
| 260 | 8.2 | 155.303030303 | 5.28 | 18.49 | 2.55 | 754966 | 9.00388585 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,72M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,54M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,75M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,29M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,8M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
